Incyte and Hengrui end PD-1 mAb deal

Incyte Corp. (NASDAQ:INCY) said in an SEC document filed Feb. 15 that it and Jiangsu Hengrui Medicine Co. Ltd. (Shanghai:3600276) agreed to terminate a deal for SHR-1210 (INCSHR1210), an anti-PD-1 mAb.

In 2015, Hengrui granted Incyte exclusive worldwide rights to develop and commercialize SHR-1210 excluding China, Hong Kong, Macau and Taiwan. Hengrui received $25 million up front and was eligible to receive up to $770 million in milestones, plus tiered high single-digit to mid double-digit royalties (see BioCentury, Sept. 7, 2015)...